• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Sep. 20, 2017

View Archived Issues

In the clinic

Incysus Ltd., of New York, submitted an IND application to the FDA for a phase I trial testing its expanded and activated allogeneic gamma-delta T cells in patients with blood cancers following haploidentical stem cell transplantation. Read More

Financings

Array Biopharma Inc., of Boulder, Colo., closed its public offering of about 24.1 million shares, including 3.1 million shares issued to cover underwriters' full overallotment option. Read More

Other news to note

Zymeworks Inc., of Vancouver, British Columbia, said Merck & Co. Inc., of Kenilworth, N.J., provided formal notification of its plans to advance a bispecific drug candidate into preclinical development. Read More

Appointments and advancments

Affimed NV, of Heidelberg, Germany, appointed Wolfgang Fischer chief operating officer. Read More

Regulatory front

As part of its educational efforts on the qualification of biomarkers to potentially streamline drug development, the FDA released new modules mapping out the process for requestors and explaining the opportunities to engage with the agency during the qualification of the biomarkers. Read More

Shanghai Fosun makes progress on stalled Gland Pharma purchase

HONG KONG – Shanghai Fosun Pharmaceutical Group Co. Ltd. has made progress on its proposed purchase of the majority stake in India's Gland Pharma Ltd., with a recent amendment stating it would acquire 74 percent of the interest in the Hyderabad-based pharmaceutical company for $1.09 billion, instead of the original proposed 86 percent for $1.26 billion. Read More

Signaling inhibitor shown to direct breast cancer metastasis

A study showing that an inhibitor of WNT signaling had differential effects on the lung and bone metastasis of breast cancer could have important implications for treating breast cancer, Chinese researchers reported in the Sept. 11, 2017, online edition of Nature Cell Biology. Read More

Tweak to Supernus ADHD trial sends shares lower

Supernus Pharmaceuticals Inc. shares fell 23.4 percent Tuesday after the company dropped one of two doses of an experimental treatment for impulsive aggression in children with attention deficit hyperactivity disorder (ADHD) that it was evaluating in twin phase III studies. Read More

Axon you shall receive: In enzyme-target bid, $30M series A cash fuels Disarm

For scientists aiming to combat the long-known problem of axonal degeneration, "the issue was that there wasn't a lever to pull, there wasn't a drug target," Disarm Therapeutics Inc.'s acting CEO, Jason Rhodes, told BioWorld. Read More

Hatch: Deduction for dividends may solve double taxation snag

The Senate Finance Committee hearing on corporate tax reform included the usual discussion about the high tax rate imposed on companies in the U.S., but the committee's chairman, Orrin Hatch (R-Utah), said he is still focused on a proposal to allow corporations to deduct dividends paid to shareholders, a move he said would serve as "a complement to a statutory corporate tax rate reduction, not a substitute." Read More

Flaws in the IPR process give rise to some very inventive patent solutions

Before making a mad dash to follow Allergan plc's lead in handing off key patents to an Indian tribe to avoid inter partes reviews (IPRs), other drug and med-tech companies may want to watch from the sidelines to see how the U.S. Supreme Court rules in a case that could doom the entire IPR process. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 26, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 25, 2025.
  • Martin Kulldorf, ACIP chair

    No vote, ACIP recurring theme at CDC confirmation hearing

    BioWorld
    Although the U.S. CDC’s Advisory Committee for Immunization Practices (ACIP) was scheduled to vote June 25 on recommendations for maternal and pediatric...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 24, 2025
  • Hands holding gears

    Kymera brings on Gilead as partner while Sanofi alters deal

    BioWorld
    Kymera Therapeutics Inc. found itself juggling partnerships by bringing one on board while going to the development bench in another. Kymera and Gilead Sciences...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe